Skip to main content

Table 1 Univariate Cox regression analysis of prognostic factors correlated with overall survival and progression-free survival

From: Preoperative anaemia and thrombocytosis predict adverse prognosis in non‐metastatic renal cell carcinoma with tumour thrombus

Characteristics

All cohort (n = 146)

Age, y, median. (IQR)

60 (54–66.25)

Sex, no. (%)

 

Male

113 (77.4)

Female

33 (22.6)

BMI, kg/m2, median. (IQR)

23.87 (21.44–26.65)

Symptom at presentation, no. (%)

 

Absent

38 (26)

Present

108 (74)

ASA score, no. (%)

 

I–II

129 (88.3)

III

17 (11.7)

Surgical approach, no. (%)

 

Open

59 (40.4)

Laparoscopic

87 (59.6)

Surgical time, min, median. (IQR)

305.5 (224.25–400)

Blood loss, ml, median. (IQR)

600 (200–1650)

Transfusion, no. (%)

61 (41.8)

Segmental resection of vena cava, no. (%)

27 (18.5)

Tumour side, no. (%)

 

Left

52 (35.6)

Right

94 (64.4)

Tumour size, cm, median. (IQR)

8.25 (6.48–10)

Tumour thrombus level, no. (%)

 

0–II

118 (80.8)

III–IV

28 (19.2)

Invasion of venous wall, no. (%)

53 (41.4)

Histology subtype, no. (%)

 

Clear cell

124 (84.9)

Non-CCRCC

22 (15.1)

Nuclear grade, no. (%)

 

I–II

61 (41.7)

III–IV

85 (58.3)

lymph node metastasis, no. (%)

9 (5.9)

Necrosis, no. (%)

66 (45.8)

SSIGN score

 

Low-risk (score 2–4)

49 (33.5)

Intermediate-risk (score 5–7)

76 (52.1)

High-risk (score 8–11)

21 (13.4)

  1. IQR interquartile range, BMI body mass index, ASA American Society of Anesthesiologists, CCRCC clear cell renal cell carcinoma